Jones Financial Companies
SAGE

Jones Financial Companies’s Sage Therapeutics SAGE Stock Holding History

Jones Financial Companies’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$110 – 4355
2025
Q2 		$110 Hold
12
– – ﹤0.01% 3946
2025
Q1 		$99 Hold
12
– – ﹤0.01% 3627
2024
Q4 		$65 Sell
12
-25
-68% -$153 ﹤0.01% 3372
2024
Q3 		$270 Sell
37
-63
-63% -$577 ﹤0.01% 2928
2024
Q2 		$1.09K Buy
+100
New +$1.28K ﹤0.01% 2274

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Jones Financial Companies's SAGE Position: Q3 2025 in Review

Jones Financial Companies sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 12 shares — an estimated $110 sold.

Jones Financial Companies first reported a position in SAGE in Q2 2024 and held it in 5 quarters. The position peaked at $1.09K in Q2 2024. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Jones Financial Companies reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jones Financial Companies sold 12 Sage Therapeutics shares in Q3 2025, an estimated $110.
  • Jones Financial Companies first reported a position in Sage Therapeutics in Q2 2024 and held it in 5 quarters.
  • Jones Financial Companies's Sage Therapeutics position peaked at $1.09K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Jones Financial Companies's 13F filing for Q3 2025, filed 4 Nov 2025.